CME Group (NASDAQ:CME) Stock Purchased Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of CME Group Inc. (NASDAQ:CME). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in CME Group stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/17/2025.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/11/2025.
• Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.

CME Group Price Performance

CME stock opened at $284.35 on Monday. The firm has a market cap of $102.47 billion, a P/E ratio of 29.41, a price-to-earnings-growth ratio of 6.76 and a beta of 0.45. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.02 and a current ratio of 1.01. CME Group Inc. has a 1 year low of $190.70 and a 1 year high of $286.48. The stock has a 50-day simple moving average of $264.47 and a 200-day simple moving average of $245.78.

CME Group (NASDAQ:CME) last released its quarterly earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.61 by $0.19. The firm had revenue of $1.64 billion during the quarter, compared to analysts’ expectations of $1.56 billion. CME Group had a return on equity of 13.62% and a net margin of 57.52%. CME Group’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.50 EPS. On average, equities analysts predict that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th will be given a $1.25 dividend. This represents a $5.00 annualized dividend and a dividend yield of 1.76%. The ex-dividend date of this dividend is Monday, June 9th. CME Group’s payout ratio is 50.30%.

Insider Buying and Selling at CME Group

In other CME Group news, Director Larry G. Gerdes sold 2,000 shares of the business’s stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $264.10, for a total value of $528,200.00. Following the completion of the transaction, the director now directly owns 38,651 shares of the company’s stock, valued at approximately $10,207,729.10. The trade was a 4.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Suzanne Sprague sold 1,500 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $256.83, for a total value of $385,245.00. Following the transaction, the chief operating officer now directly owns 8,036 shares in the company, valued at approximately $2,063,885.88. This represents a 15.73% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,726 shares of company stock valued at $8,975,813. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CME Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. SeaCrest Wealth Management LLC lifted its stake in shares of CME Group by 3.0% in the first quarter. SeaCrest Wealth Management LLC now owns 1,379 shares of the financial services provider’s stock valued at $366,000 after buying an additional 40 shares during the period. New Age Alpha Advisors LLC boosted its stake in CME Group by 50.0% in the 4th quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider’s stock valued at $30,000 after buying an additional 43 shares in the last quarter. OneAscent Financial Services LLC boosted its stake in CME Group by 4.0% in the 1st quarter. OneAscent Financial Services LLC now owns 1,106 shares of the financial services provider’s stock valued at $293,000 after buying an additional 43 shares in the last quarter. Avidian Wealth Enterprises LLC grew its position in CME Group by 2.6% in the fourth quarter. Avidian Wealth Enterprises LLC now owns 1,769 shares of the financial services provider’s stock valued at $411,000 after acquiring an additional 45 shares during the period. Finally, Ballentine Partners LLC raised its stake in CME Group by 0.8% during the first quarter. Ballentine Partners LLC now owns 5,828 shares of the financial services provider’s stock worth $1,546,000 after acquiring an additional 45 shares in the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CME has been the subject of a number of recent analyst reports. Bank of America raised their price target on shares of CME Group from $200.00 to $219.00 and gave the company an “underperform” rating in a report on Wednesday, April 2nd. Piper Sandler raised their target price on CME Group from $275.00 to $283.00 and gave the company an “overweight” rating in a research note on Tuesday, April 8th. Oppenheimer lifted their target price on CME Group from $269.00 to $279.00 and gave the stock an “outperform” rating in a research report on Friday, April 11th. Keefe, Bruyette & Woods increased their price target on CME Group from $265.00 to $273.00 and gave the company a “market perform” rating in a report on Thursday, April 24th. Finally, Erste Group Bank upgraded CME Group to a “strong-buy” rating in a research note on Monday, March 17th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $256.80.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.